Obtenção, caracterização e avaliação físico-química de cocristais de ácido cinâmico

One of the limiting steps for the Active Pharmaceutical Ingredient (API) to be absorved by oral ways and to act pharmacologically, is its previous solubilization in the aqueous means. Many candidates for IFAs have low aqueous solubility, and to alternatively offer physical or chemical modificatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Santos, Jonh Anderson Borges dos
Outros Autores: Aragão, Cícero Flávio Soares
Formato: Dissertação
Idioma:pt_BR
Publicado em: Brasil
Assuntos:
Endereço do item:https://repositorio.ufrn.br/jspui/handle/123456789/27431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Descrição
Resumo:One of the limiting steps for the Active Pharmaceutical Ingredient (API) to be absorved by oral ways and to act pharmacologically, is its previous solubilization in the aqueous means. Many candidates for IFAs have low aqueous solubility, and to alternatively offer physical or chemical modifications in these substances, are very necessary. Cinnamic acid (AC) is an IFA candidate that has studies demonstrating several important pharmacological activities, such as antimicrobial and antitumor, with low toxicity. The use of cocrystallization is one of the main strategies applied to improve the aqueous solubility of the IFA. The aim was to obtain the cocrystals of CA and its characterization and physical-chemical evaluation. Physical mixtures (MFs) were prepared manually by mixing the powders, and the cocrystals (CCs) were obtained by solvent evaporation in stoichiometric amounts of IFA and copolymer in molar ratio 1: 1. The characterization was performed using techniques such as X-ray Diffraction (XRD), Differential Scanning Calorimetry (DSC), Infrared Spectroscopy with Fourier Transform (FTIR) and Scanning Electron Microscopy (SEM). For the physical and chemical evaluation of the possible CCs, an analytical method was developed and optimized by Ultra High Pressure Liquid Chromatography (UHPLC) and validated according to the current resolution. The physicochemical evaluation of the cocristais was performed by water saturation solubility test, and the solubility determination was expressed by concentration measurements. The results of characterization by XRD evaluation of the powder showed that the interaction of the AC with 8 coformers did not show changes in the diffraction pattern of the solid samples obtained after rotary evaporation. However, the interaction of CA with other 3 coformers, CAF, NIC and TIA in the obtained samples of CCs, showed changes by powder XRD in the diffraction pattern characterized by the appearance of new unidentified peaks in the diffraction pattern of the isolated pharmaceutical ingredients. From the DSC curves, it was noticed that the fusion of the CCs samples occurred at lower temperatures compared to the isolated pharmaceutical ingredients. The FTIR spectra showed shifts of the main vibrations to lower frequencies, related to the possible hydrogen connections created. SEM photomicrographs showed a brief change in the crystalline habit of CCs. The analytical method by UHPLC was developed in a gradient mode with mobile phase 0.1% trifluoroacetic acid (TFA) in ultrapure water and methanol under optimized chromatographic conditions. The method was selective, linear, precise, accurate and robust. After solubility test, the saturation solubility in aqueous medium for the isolated CA was 0.55 mg.mL-1, and in the CCs with CAF, NIC and TIA were 0.9, 0.86 and 0.64 mg.mL-1, being it considereted a significant increase of 63%, 56% and 16%, respectively, in the aqueous solubility of the IFA. Findings proved the importance of the use of solid state characterization techniques in the identification of cocrystals, however, it is still necessary to introduce others confirmatory techniques, such as single crystal XRD. The increase in the aqueous solubility of CA correlates directly with the modifications provided by the cocrystals, which may favor the production of a technologically more favorable pharmaceutical product.